{
    "nctId": "NCT01382082",
    "briefTitle": "Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy",
    "officialTitle": "Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment, Post-Treatment, at Six Month Follow-Up, and Long-Term Follow-Ups",
    "overallStatus": "ENROLLING_BY_INVITATION",
    "conditions": "Breast Cancer, Lymphoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1432,
    "primaryOutcomeMeasure": "Short-term memory",
    "eligibilityCriteria": "Inclusion Criteria:\n\nSubjects Receiving Chemotherapy:\n\n* Have a diagnosis of invasive breast cancer (stage I-IIIC) or intermediate or high-grade\\* lymphoma (\\*defined by the treating physician)\n* Be scheduled to begin a course of chemotherapy\n* Oral chemotherapy is acceptable\n* Previous or concurrent treatment with hormones or biological response modifiers is acceptable. (Subjects receiving biological response modifiers only are not eligible).\n* Be chemotherapy na\u00efve\n* Life expectancy greater than 10 months\n* Be able to speak and read English\n* Give written informed consent\n\nInclusion Criteria, Controls:\n\n* Must be the same gender as the subject receiving chemotherapy\n* Must be within 5 years of the age of the subject receiving chemotherapy\n* Life expectancy greater than 10 months\n* Be able to speak and read English\n* Give written informed consent\n* Must be willing to participate in the study for the entire period\n\nInclusion Criteria, Long-Term Followup Study:\n\n* Must be a subject who had breast cancer, or control who was paired with that subject with breast cancer, who provided CANTAB data at any time-point during assessments 1 through 3.\n\nExclusion Criteria:\n\nSubjects Receiving Chemotherapy:\n\n* Must not be currently hospitalized or have been hospitalized within the last year for a psychiatric illness\n* Must not be diagnosed with a neurodegenerative disease\n* Must not have primary central nervous system (CNS) disease\n* Must not have received chemotherapy in the past\n* Must not be scheduled to receive concurrent radiation treatment\n* Must not have metastatic disease (subjects with breast cancer)\n* Must not be pregnant\n* Must not be colorblind\n\nExclusion Criteria, Controls:\n\n* Must not be currently hospitalized or have been hospitalized within the last year for a psychiatric illness\n* Must not be diagnosed with a neurodegenerative disease\n* Must not have primary CNS disease\n* Must not have been diagnosed with cancer or previously have received chemotherapy\n* Must not be pregnant or plan on becoming pregnant during the study period\n* Must not be colorblind\n\nExclusion Criteria, Long-Term Followup Study:\n\n* Must not have dementia or any severe neurodegenerative disease that would prohibit the ability to complete cognitive testing.\n* Must not be colorblind",
    "sex": "ALL",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}